Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03034915
Registration number
NCT03034915
Ethics application status
Date submitted
25/01/2017
Date registered
27/01/2017
Date last updated
11/03/2020
Titles & IDs
Public title
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Query!
Scientific title
A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Query!
Secondary ID [1]
0
0
2016-002513-22
Query!
Secondary ID [2]
0
0
201749
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - UMEC/VI 62.5/25 mcg via ELLIPTA
Treatment: Drugs - UMEC 62.5 mcg via ELLIPTA
Treatment: Drugs - Salmeterol 50 mcg via DISKUS
Treatment: Drugs - Placebo via ELLIPTA
Treatment: Drugs - Placebo via DISKUS
Experimental: UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS - Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
Experimental: UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS - Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
Experimental: Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA - Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
Treatment: Drugs: UMEC/VI 62.5/25 mcg via ELLIPTA
ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
Treatment: Drugs: UMEC 62.5 mcg via ELLIPTA
The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
Treatment: Drugs: Salmeterol 50 mcg via DISKUS
The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Treatment: Drugs: Placebo via ELLIPTA
Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
Treatment: Drugs: Placebo via DISKUS
Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24
Query!
Assessment method [1]
0
0
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 at Week 24 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on the previous day. Baseline trough FEV1 is the mean of the values measured at 30 minutes and 5 minutes pre-dose on Day 1. Change from Baseline was calculated as the trough FEV1 value on Week 24 minus the Baseline value. Analysis was performed using a repeated measures model (MMRM) with covariates of Baseline FEV1, geographical region, stratum (number of bronchodilators per day during run-in), visit, treatment, visit by Baseline and visit by treatment interaction. ITT population comprised of all randomized participants (excluding those who were randomized in error) who received at least one dose of study medication.
Query!
Timepoint [1]
0
0
Baseline (Pre-dose on Day 1) and Week 24
Query!
Secondary outcome [1]
0
0
Self Administered Computerized (SAC) Transient Dyspnea Index (TDI) Focal Score at Week 24
Query!
Assessment method [1]
0
0
TDI focal score comprises of 3 individual scales (Functional Impairment, Magnitude of Task, Magnitude of Effort). Each of these scales had a possible score ranging from -6 to +6, lower scores indicates impairment. TDI focal score was calculated as the sum of 3 individual scores (range is -18 to +18). Lower score indicates deterioration of dyspnea. If a score is missing for any of the three scales, then the TDI focal score was set to missing. Analysis was performed using mixed model repeated measures (MMRM) with covariates of SAC BDI focal score, geographical region, stratum (no. of bronchodilators per day during run-in), visit, treatment, visit by SAC BDI and visit by treatment interactions.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [2]
0
0
Percentage of TDI Responders According to SAC TDI Focal Score
Query!
Assessment method [2]
0
0
TDI focal score comprises of 3 individual scales (Functional Impairment, Magnitude of Task, Magnitude of Effort). Each of these scales had a possible score ranging from -6 to +6, lower scores indicates impairment. TDI focal score was calculated as the sum of 3 individual scores (range is -18 to +18). Lower score indicates deterioration of dyspnea. If a score is missing for any of the three scales, then TDI focal score was set to missing. A participant was considered as a responder if the on-treatment TDI focal score was at least 1 unit at that visit. Non-response was SAC TDI focal score of less than 1 unit or a missing SAC TDI focal score with no subsequent non-missing on-treatment scores. Analysis was performed using a generalized linear mixed model with treatment as an explanatory variable and visit, SAC BDI focal score, stratum (no. of bronchodilators per day during run-in), geographical region, visit by SAC BDI and visit by treatment interactions included as covariates.
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline in Evaluating Respiratory Symptoms (E-RS) Total Score
Query!
Assessment method [3]
0
0
The E-RS is intended to capture information related to respiratory symptoms. A daily symptom score for E-RS is derived by summing 11 item-scores. The domains include: respiratory symptoms (RS)-breathlessness (RS-BRL comprised of 5 items, score range [0-17]), RS-cough and sputum (RS-CSP comprised of 3 items, score range [0-11]), and RS-chest symptoms (RS-CSY comprised of 3 items, score range [0-12]). Total score ranged between 0-40 and higher values indicates severe respiratory symptoms. The instrument was completed each night prior to going to bed. Baseline E-RS score is the mean within-participant daily score over 7 days prior to randomization. Change from Baseline is the difference at Week 21-Week 24 value and Baseline value. Analysis was performed using MMRM with covariates of Baseline score, geographical region, stratum (no. of bronchodilators per day during run-in), 4-weekly period, treatment, 4-weekly period by Baseline and 4-weekly period by treatment interactions.
Query!
Timepoint [3]
0
0
Baseline (Pre-dose on Day 1) and Week 21 to Week 24
Query!
Secondary outcome [4]
0
0
Mean Change From Baseline in E-RS Subscale Score
Query!
Assessment method [4]
0
0
The E-RS is intended to capture information related to respiratory symptoms. A daily symptom score for E-RS is derived by summing 11 item-scores. The domains include: respiratory symptoms (RS)-breathlessness (RS-BRL comprised of 5 items, score range [0-17]), RS-cough and sputum (RS-CSP comprised of 3 items, score range [0-11]), and RS-chest symptoms (RS-CSY comprised of 3 items, score range [0-12]). Total score ranged between 0-40 and higher values indicates severe respiratory symptoms. The instrument was completed each night prior to going to bed. Baseline E-RS score is the mean within-participant daily score over 7 days prior to randomization. Change from Baseline is the difference at Week 21-Week 24 value and Baseline value. Analysis was performed using MMRM with covariates of Baseline score, geographical region, stratum (no. of bronchodilators per day during run-in), 4-weekly period, treatment, 4-weekly period by Baseline and 4-weekly period by treatment interactions.
Query!
Timepoint [4]
0
0
Baseline (Pre-dose on Day 1) and Week 21 to Week 24
Query!
Secondary outcome [5]
0
0
Percentage of E-RS Responders According to E-RS Total Score
Query!
Assessment method [5]
0
0
The E-RS is intended to capture information related to respiratory symptoms. A daily symptom score for E-RS is derived by summing 11 item-scores. The domains include: RS-BRL comprised of 5 items, score range (0-17); RS-CSP comprised of 3 items, score range (0-11); and RS-CSY comprised of 4 items, score range (0-12). Total score ranged between 0-40 and higher values indicates severe respiratory symptoms. The instrument was completed each night prior to going to bed. Response is defined as an E-RS total score of at least 2 or 3.35 below Baseline. Participants with a Baseline but all missing post-Baseline data are also considered a non-responder. Analysis was performed using a generalized linear mixed model with treatment as an explanatory variable and four-weekly period, Baseline score, stratum (no. of bronchodilators per day during run-in), geographical region, four-weekly period by baseline and four-weekly period by treatment interactions included as covariates.
Query!
Timepoint [5]
0
0
Week 21 to Week 24
Query!
Secondary outcome [6]
0
0
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score
Query!
Assessment method [6]
0
0
SGRQ is a disease-specific questionnaire designed to measure impact of respiratory disease and its treatment on HRQoL of participants with COPD. It contains 14 questions with a total of 40 items grouped into domains (Symptoms, Activity and Impacts). SGRQ total score was calculated as 100 multiplied by summed weights from all positive items divided by sum of weights for all items in questionnaire. It ranges from 0 to 100, higher score indicates poor HRQoL. Baseline is last non-missing score recorded prior to dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the value at Week 24. Analysis was performed using mixed model repeated measures (MMRM) with covariates of Baseline SGRQ total score, geographical region, stratum (no. of bronchodilators per day during run-in), visit, treatment, visit by Baseline and visit by treatment interactions.
Query!
Timepoint [6]
0
0
Baseline (Pre-dose on Day 1) and Week 24
Query!
Secondary outcome [7]
0
0
Percentage of Responders Based on the Saint (St) George Respiratory Questionnaire COPD Specific (SGRQ) Total Score
Query!
Assessment method [7]
0
0
SGRQ is a disease-specific questionnaire designed to measure impact of respiratory disease and its treatment on HRQoL of participants with COPD. It contains 14 questions with a total of 40 items grouped into domains (Symptoms, Activity and Impacts). SGRQ total score was calculated as 100 multiplied by summed weights from all positive items divided by sum of weights for all items in questionnaire. It ranges from 0 to 100, higher score indicates poor HRQoL. Analysis was performed using a generalized linear mixed model with treatment as an explanatory variable and visit, Baseline SGRQ score, stratum (no. of bronchodilators per day during run-in), geographical region, visit by Baseline and visit by treatment interactions included as covariates. Response was defined as an SGRQ total score of 4 or more units below Baseline.
Query!
Timepoint [7]
0
0
Week 24
Query!
Secondary outcome [8]
0
0
Change From Baseline in COPD Assessment Test (CAT)
Query!
Assessment method [8]
0
0
The CAT is a participant-completed instrument designed to provide a simple and reliable measure of health status in COPD for the assessment and long-term follow-up of the individual participant. The CAT consists of eight items, each formatted on a differential scale. Participants rated their experience on a 6-point scale for each question, ranging from 0 (no impact) to 5 (high impact). A total CAT score was calculated by summing the non-missing scores on the eight items ranging from 0 to 40 with higher scores indicating greater disease impact. Baseline is defined as the last non-missing score recorded prior to dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the value at Week 24. Analysis was performed using mixed model repeated measures (MMRM) with covariates of Baseline CAT score, geographical region, stratum (no. of bronchodilators per day during run-in), visit, treatment, visit by Baseline and visit by treatment interactions.
Query!
Timepoint [8]
0
0
Baseline (Pre-dose on Day 1) and Week 24
Query!
Secondary outcome [9]
0
0
Percentage of Responders According to CAT
Query!
Assessment method [9]
0
0
The CAT is a participant-completed instrument designed to provide a simple and reliable measure of health status in COPD for the assessment and long-term follow-up of the individual participant. The CAT consists of eight items. Participants rated their experience on a 6-point scale for each question, ranging from 0 (no impact) to 5 (high impact). A total CAT score was calculated by summing the non-missing scores on the eight items ranging from 0 to 40 with higher scores indicate greater disease impact. Response was defined as an CAT score of >=2 below Baseline. Non response was defined as CAT score <2 units below Baseline or a missing CAT score with no subsequent on treatment scores. Analysis performed using a generalized linear mixed model with treatment as an explanatory variable and visit, baseline CAT score, stratum (no. of bronchodilators per day during run-in), geographical region, visit by baseline and visit by treatment interactions included as covariates.
Query!
Timepoint [9]
0
0
Week 24
Query!
Secondary outcome [10]
0
0
Number of Participants With on Treatment Adverse Events (AE) and Serious Adverse Events (SAE)
Query!
Assessment method [10]
0
0
An AE is any untoward medical occurrence in a participant or clinical investigation participant , temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events associated with liver injury and impaired liver function based on pre-defined criteria were categorized as SAE.
Query!
Timepoint [10]
0
0
Up to Week 24
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- 40 years or older at date of signing informed consent at Screening Visit 1
- Outpatient with a diagnosis of COPD
- Persistent airflow limitations as indicated by a pre and post-albuterol/salbutamol
FEV1/FVC ratio of <0.70 and a post-albuterol/salbutamol FEV1 of >=30% to <=80%
predicted normal values at Screening Visit 1.
- A CAT score of >=10 at Screening Visit 1
- Current or former cigarette smokers with a history of cigarette smoking of >=10
pack-years (number of pack years = [number of cigarettes per day / 20] multiplied by
number of years smoked [e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per
day for 20 years both equal 10 pack-years]). Former smokers are defined as those who
have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use
cannot be used to calculate pack-year history.
- Male and female subjects are eligible to participate in the study. A female subject is
eligible to participate if she is not pregnant (as confirmed by a negative urine human
chorionic gonadotrophin test), not lactating, and at least one of the following
conditions applies: non-reproductive potential defined as pre-menopausal females with
documented tubal ligation or documented hysteroscopic tubal occlusion procedure with
follow-up confirmation of bilateral tubal occlusion or hysterectomy or documented
bilateral oophorectomy. Postmenopausal defined as 12 months of spontaneous amenorrhea.
In questionable cases, a blood sample with simultaneous follicle stimulating hormone
and estradiol levels consistent with menopause must be tested. Females on hormone
replacement therapy (HRT) and whose menopausal status is in doubt will be required to
use one of the highly effective contraception methods if they wish to continue their
HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of
post-menopausal status prior to study enrolment.
A female subject with reproductive potential is eligible to participate if she is not
pregnant and agrees to follow one of the highly effective methods for avoiding pregnancy in
females of reproductive potential from 30 days prior to the first dose of study medication
and until (at least five terminal half-lives or until any continuing pharmacologic effect
has ended, whichever is longer) after the last dose of study medication and completion of
the follow-up visit. The investigator is responsible for ensuring that subjects understand
how to properly use methods of contraception.
- Capable of giving signed informed consent prior to study participation.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria
- A current diagnosis of asthma (Subjects with a prior history of asthma are eligible if
they have a current diagnosis of COPD, which is the primary cause of their respiratory
symptoms).
- Subjects with known alpha-antitrypsin deficiency as the underlying cause of COPD
- Subjects with active tuberculosis are excluded. Subjects with other respiratory
disorders (e.g., clinically significant: bronchiectasis, sarcoidosis, lung fibrosis,
pulmonary hypertension, interstitial lung diseases) are excluded if these conditions
are the primary cause of their respiratory symptoms.
- Current active liver or biliary disease (with the exception of Gilbert's syndrome or
asymptomatic gallstones or otherwise stable chronic liver disease as per investigator
assessment); stable chronic liver disease should generally be defined by the absence
of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric
varices, or persistent jaundice, or cirrhosis; chronic stable hepatitis B and C (e.g.,
presence of hepatitis B surface antigen or positive hepatitis C antibody test result
or within 3 months prior to first dose of study treatment) are acceptable if subject
otherwise meets entry criteria.
- Subjects with unstable or life threatening cardiac disease. The investigational
product should be used with caution in subjects with severe cardiovascular disease. In
the opinion of the investigator, use will only be considered if the benefit is likely
to outweigh the risk in conditions such as myocardial infarction or unstable angina in
the last 6 months, or unstable or life threatening cardiac arrhythmia requiring
intervention in the last 3 months, or New York Heart Association Class IV heart
failure.
- The investigator will determine the clinical significance of each abnormal
electrocardiogram (ECG) finding in relation to the subject's medical history and
exclude subjects who would be at undue risk by participating in the trial. Subjects
with the following abnormalities are excluded from participation in the study: atrial
fibrillation with rapid ventricular rate >120 beats per minute (bpm), sustained or
non-sustained ventricular tachycardia, second degree heart block Mobitz type II or
third degree heart block (unless pacemaker or defibrillator had been inserted).
- Subjects with medical conditions such as narrow-angle glaucoma, urinary retention,
prostatic hypertrophy, or bladder neck obstruction will be excluded unless, in the
opinion of the study physician, the benefit outweighs the risk.
- Any subject who is considered unlikely to survive the duration of the study period or
has any rapidly progressing disease or immediate life-threatening illness (e.g.,
cancer). In addition, any subject who has any other condition (e.g., neurological
condition) that is likely to affect respiratory function will not be included in the
study.
- Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1. Pneumonia
and/or moderate or severe COPD exacerbation that has not resolved at least 14 days
prior to Screening Visit 1and at least 30 days following the last dose of
oral/systemic corticosteroids (if applicable).
- Subjects who had received inhaled corticosteroids (ICS) or ICS/ long-acting
beta-agonist for the treatment of COPD in the 6 weeks prior to Screening Visit1.
- Subjects who had >1 moderate exacerbation in the 12 months prior to Screening Visit 1,
or one severe exacerbation requiring hospitalization in the 12 months prior to
Screening Visit 1.
- Other respiratory tract infections that have not resolved at least 7 days prior to
Screening Visit 1.
- Subjects with lung volume reduction surgery (including procedures such as
endobronchial valves) within the 12 months prior to Screening Visit 1.
- Use of long-term oxygen therapy described as resting oxygen therapy >3 Liter
(L)/minute (min) at screening required to maintain adequate oxygenation (e.g., oxygen
saturation in arterial blood [SaO2] >90%; oxygen use <=3 L/min flow is not
exclusionary, and subjects may adjust oxygen levels up or down as needed during the
study.)
- Use of ICS within 6 weeks prior to Screening Visit 1; use of depot corticosteroids
within 12 weeks prior to Screening Visit 1; use of systemic, oral or parenteral
corticosteroids within 6 weeks prior to Screening Visit 1 (Localized corticosteroid
injections [e.g., intra-articular and epidural] are permitted); use of antibiotics
(for lower respiratory tract infection) within 6 weeks prior to Screening Visit 1; use
of phosphodiesterase 4 (PDE4) inhibitor (e.g., roflumilast) within 14 days prior to
Screening Visit 1; use of long-acting beta-agonist/ ICS combination products within 6
weeks prior to Screening Visit 1; use of theophyllines within 48 hours prior to
Screening Visit 1; use of oral long-acting beta2-agonists within 48 hours and
short-acting beta2-agonists within 12 hours prior to Screening Visit 1; use of inhaled
short-acting beta2-agonists within 4 hours prior to Screening Visit 1 (use of study
provided albuterol/salbutamol is permitted during the study, except in the 4-hour
period prior to spirometry testing); use of inhaled short-acting anticholinergics
within 4 hours prior to Screening Visit 1; use of inhaled short-acting
anticholinergic/short-acting beta2-agonist combination products within 4 hours prior
to Screening Visit 1; use of any other investigational medication within 30 days or
within 5 drug half-lives (whichever is longer) prior to Screening Visit 1.
- Subject unable to withhold albuterol/salbutamol for the 4-hour period required prior
to spirometry testing at each study visit.
- Regular use (prescribed for daily/ regular use, not for as-needed use) of short-acting
bronchodilators (e.g., albuterol/salbutamol).
- A known or suspected history of alcohol or drug abuse within 2 years prior to
Screening Visit 1 that in the opinion of the investigator would prevent the subject
from completing the study procedures.
- Any history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor
antagonist, sympathomimetic, lactose/milk protein or magnesium stearate.
- Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks
prior to Screening Visit 1. Subjects who are in the maintenance phase of a pulmonary
rehabilitation program are not excluded.
- Subject is an investigator, sub-investigator, study coordinator, employee of a
participating investigator or study site, or immediate family member of the
aforementioned that is involved in this study.
- In the opinion of the investigator, any subject who is unable to read and/or would not
be able to complete questionnaires on the electronic diary.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/06/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/06/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2696
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Coffs Harbour
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Darlinghurst, Sydney
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Kanwal
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Port Macquarie
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst, Sydney
Query!
Recruitment postcode(s) [3]
0
0
2259 - Kanwal
Query!
Recruitment postcode(s) [4]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [5]
0
0
2010 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Louisiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nebraska
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Mexico
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oregon
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
South Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
West Virginia
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Buenos Aires
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Córdova
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Entre Ríos
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Mendoza
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Santa Fe
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Capital Federal
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Ciudad Autonoma de Buenis Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Monte Grande
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
San Miguel de Tucumán
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Santa Rosa
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Tucumán
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
New Brunswick
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Nova Scotia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Ontario
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Marseille cedex 03
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Nice
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Perpignan
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Pessac cedex
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Baden-Wuerttemberg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bayern
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Brandenburg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hessen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Mecklenburg-Vorpommern
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Niedersachsen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Nordrhein-Westfalen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Rheinland-Pfalz
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Sachsen-Anhalt
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Sachsen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Schleswig-Holstein
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Thueringen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Berlin
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Frankfurt
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Hamburg
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Leipzig
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Campania
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Emilia-Romagna
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Friuli-Venezia-Giulia
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Lombardia
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Puglia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Sicilia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Toscana
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Umbria
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Napoli
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
San Pietro Vernotico
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Jalisco
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Almere
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Beek
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Breda
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Den Haag
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Heerlen
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Hoorn
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Kloosterhaar
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Rotterdam
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Zutphen
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Gauteng
Query!
Country [74]
0
0
South Africa
Query!
State/province [74]
0
0
Mpumalanga
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Bloemfontein
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Cape Town
Query!
Country [77]
0
0
South Africa
Query!
State/province [77]
0
0
Durban
Query!
Country [78]
0
0
South Africa
Query!
State/province [78]
0
0
Mowbray
Query!
Country [79]
0
0
South Africa
Query!
State/province [79]
0
0
Panorama
Query!
Country [80]
0
0
South Africa
Query!
State/province [80]
0
0
Reiger Park
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Andalucia
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Alicante
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Centelles (Barcelona)
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Gerona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Mérida (Badajoz)
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Peralada( Girona)
Query!
Country [88]
0
0
Sweden
Query!
State/province [88]
0
0
Borås
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Göteborg
Query!
Country [90]
0
0
Sweden
Query!
State/province [90]
0
0
Höllviken
Query!
Country [91]
0
0
Sweden
Query!
State/province [91]
0
0
Linköping
Query!
Country [92]
0
0
Sweden
Query!
State/province [92]
0
0
Luleå
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Lund
Query!
Country [94]
0
0
Sweden
Query!
State/province [94]
0
0
Malmö
Query!
Country [95]
0
0
Sweden
Query!
State/province [95]
0
0
Skövde
Query!
Country [96]
0
0
Sweden
Query!
State/province [96]
0
0
Stockholm
Query!
Country [97]
0
0
Sweden
Query!
State/province [97]
0
0
Uppsala
Query!
Country [98]
0
0
Sweden
Query!
State/province [98]
0
0
Örebro
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
COPD is characterized by an airflow limitation, which is not fully reversible, usually
progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a
major cause of disability and anxiety associated with the disease. In addition, COPD is
associated with poor health-related quality of life (HRQoL). Pharmacologic therapy is used to
improve lung function, reduce symptoms, reduce the frequency and severity of exacerbations,
and also to improve health status and exercise tolerance.
This is a multi-center, randomized, double blind, double dummy, 3-arm parallel group study to
compare umeclidinium/vilanterol (62.5/25 microgram [mcg], once daily), umeclidinium (62.5
mcg, once daily), and salmeterol (50 mg, twice daily) in male and female subjects with COPD.
The primary purpose of this study is to demonstrate improvements in lung function for
subjects treated with UMEC/VI compared with UMEC for 24 weeks.
Approximately 2424 subjects will be randomized across 3 parallel arms in 1:1:1 ratio.
Subjects will be stratified based on long-acting bronchodilator usage during the run-in
period (none, one or 2 long-acting bronchodilators per day). Subjects will receive either
UMEC/VI inhalation powder (62.5/25 microgram [mcg] once daily) administered via the ELLIPTA®
dry powder inhaler (DPI) and placebo twice daily via DISKUS® DPI; or UMEC (62.5 mcg once
daily) administered via the ELLIPTA DPI and placebo twice daily via DISKUS DPI or salmeterol
(50 mcg twice daily [BID]) administered via the DISKUS DPI and placebo once daily via ELLIPTA
DPI. The duration of the study will be 29 to 31 weeks including a pre-screening period of 2
weeks, run-in period of 4 weeks, treatment period of 24 weeks and follow-up period of 1 week.
ELLIPTA and DISKUS are trademarks of GSK group of companies.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03034915
Query!
Trial related presentations / publications
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03034915
Download to PDF